世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

セフトリアキソン市場(適応症:尿路感染症、腹腔内感染症、心内膜炎、急性細菌性中耳炎、髄膜炎、肺炎、その他)-世界の産業分析、サイズ、シェア、成長、トレンド、予測、2022-2031年


Ceftriaxone Market (Indication: Urinary Tract Infections, Intra-abdominal Infections, Endocarditis, Acute Bacterial Otitis Media, Meningitis, Pneumonia, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

セフトリアキソン市場 - レポートの範囲 TMRの調査レポート「世界のセフトリアキソン市場」は、2022年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動... もっと見る

 

 

出版社 出版年月 電子版価格 ページ数 言語
Transparency Market Research
トランスペアレンシーマーケットリサーチ
2022年12月14日 US$5,795
シングルユーザライセンス
ライセンス・価格情報・注文方法はこちら
170 英語

 

サマリー

セフトリアキソン市場 - レポートの範囲
TMRの調査レポート「世界のセフトリアキソン市場」は、2022年から2031年までの予測期間における市場の指標について貴重な洞察を得るために、過去だけでなく現在の成長動向と機会も調査しています。本レポートでは、2021年を基準年、2031年を予測年として、2017年から2031年の期間における世界のセフトリアキソン市場の収益を提供します。また、2022年から2031年までの世界のセフトリアキソン市場の年間平均成長率(CAGR %)を掲載しています。

本レポートは、広範な調査を経て作成されました。一次調査では、主要なオピニオンリーダー、業界リーダー、オピニオンメーカーへのインタビューを実施しました。二次調査では、セフトリアキソン市場を理解するために、主要企業の製品資料、年次報告書、プレスリリース、関連文書などを参照した。

二次調査には、インターネットソース、政府機関、ウェブサイト、業界団体の統計データも含まれます。アナリストは、トップダウンアプローチとボトムアップアプローチを組み合わせて、世界のセフトリアキソン市場の様々な属性を調査しました。

本レポートには、調査範囲に含まれる様々なセグメントの成長動向のスナップショットとともに、詳細なエグゼクティブサマリーが含まれています。さらに、世界のセフトリアキソン市場における競争ダイナミクスの変化にも光を当てています。これらは、既存の市場関係者だけでなく、世界のセフトリアキソン市場への参入を検討している企業にとっても貴重なツールになります。

本レポートでは、世界のセフトリアキソン市場の競争環境について掘り下げています。世界のセフトリアキソン市場で活動する主要企業が特定され、これらの各企業が様々な属性でプロファイル化されています。会社概要、財務状況、最近の動向、SWOTは、本レポートで紹介されている世界のセフトリアキソン市場のプレイヤーの属性です。

研究方法論

調査方法は、徹底的な一次調査と二次調査を組み合わせて、セフトリアキソン市場を分析する予定です。

二次調査

二次調査には、企業の文献、技術文書、特許データ、インターネット上の情報源、政府ウェブサイト、業界団体、機関などの統計データなどの検索が含まれます。これは、正確なデータを入手し、業界関係者の洞察を得て、ビジネスチャンスを認識するための最も信頼性が高く、効果的で成功した方法であることが証明されています。

一般的に参照する二次研究資料ですが、これらに限定されるものではありません:

企業ウェブサイト、プレゼンテーション、アニュアルレポート、ホワイトペーパー、テクニカルペーパー、製品パンフレット
社内外の独自データベースや関連特許の紹介
各国政府資料、統計データベース、マーケットレポートなど
市場に参入している企業に特化したニュース記事、プレスリリース、ウェブキャストを配信しています。

具体的な二次資料

業界の情報源
WorldWideScience.org
エルゼビア社(Elsevier, Inc.
米国国立衛生研究所(NIH)
パブコメ
エヌシーバイ
ヘルスケアサービス部門
貿易データソース
トレードマップ
国連コムトレード
トレードアトラス
会社情報
OneSource Business Browser
フーバーの
ファクティバ
ブルームバーグ
M&A(合併・買収
トムソン M&A
マーチャースタット
深遠

一次調査

調査期間中、幅広い業界関係者やオピニオンリーダーとの綿密なインタビューやディスカッションを実施しました。調査の大部分は一次調査であり、二次調査によって補完されています。

データおよび分析の検証のため、業界関係者やコメンテーターへの一次インタビューを継続的に実施しています。典型的なリサーチ・インタビューは、以下のような機能を果たしています:

市場規模、市場動向、成長トレンド、競争環境、展望などに関する生の情報を提供します。
二次調査結果の検証・強化に役立つ
分析チームの専門知識と市場理解のさらなる発展
地域ごとの市場、カテゴリー、セグメント、サブセグメントについて、電子メールでのやりとり、電話取材、対面取材を含むプライマリーリサーチを実施。

このようなプロセスに通常参加する参加者は、これらに限定されるものではありません:

業界関係者の方マーケティング/プロダクトマネージャー、マーケットインテリジェンスマネージャー、リージョナルセールスマネージャー
購買・調達担当者、技術担当者、販売代理店
外部の専門家:投資銀行、バリュエーション専門家、特定市場に特化したリサーチ・アナリスト
各業界に対応した各分野の専門家であるキーオピニオンリーダー。

主な参加者のリスト(ただし、これらに限定されない):

アドバンスト・オンコセラピーPLC
Danfysik A/S
株式会社日立製作所
IBA ワールドワイド
メビオンメディカルシステムズ株式会社

データの三角測量:二次資料・一次資料」から抽出された情報は、四半期ごとに更新される「TMR Knowledge Repository」と照合されます。

市場推定:市場規模の推定には、製品の特徴、技術の更新、地理的存在、製品の需要、販売データ(金額または数量)、過去の前年比成長率などの詳細な調査が含まれます。また、市場規模や予測を導き出すために、他のアプローチも活用した。ハードデータがない場合は、包括的なデータセットを作成するためにモデリング技法を採用した。厳密な方法論を採用し、入手可能なハードデータと以下のデータタイプを相互参照し、推定値を作成した:

人口動態データ:医療費支出、インフレ率、その他
産業指標研究開発投資、技術段階、インフラ、部門成長、設備など

市場予測:市場の促進要因、阻害要因/課題、機会を考慮し、他のセグメント/サブセグメントに対するメリット/デメリットを考慮した上で、様々なセグメントの市場予測を行います。ビジネス環境、過去の販売パターン、アンメットニーズ、競争力、国別の手術データなども、市場予測を導き出すために考慮される重要な要素のひとつです。

ページTOPに戻る


目次

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Market Overview
3.2. Introduction
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunity
4.4. Global Ceftriaxone Market Forecast
4.5. Global Ceftriaxone Market Outlook
5. Market Outlook
5.1. Key Market Trends
5.2. Regulatory Scenario, by Region
5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Ceftriaxone Market Analysis and Forecast, by Indication
6.1. Introduction
6.2. Global Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
6.3. Global Ceftriaxone Market Forecast, by Indication
6.3.1. Urinary Tract Infections
6.3.2. Intra-abdominal Infections
6.3.3. Endocarditis
6.3.4. Acute Bacterial Otitis Media
6.3.5. Meningitis
6.3.6. Pneumonia
6.3.7. Others
7. Global Ceftriaxone Market Analysis and Forecast, by Distribution Channel
7.1. Introduction
7.2. Global Ceftriaxone Market Value Share Analysis, by Distribution Channel
7.3. Global Ceftriaxone Market Forecast, by Distribution Channel
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Global Ceftriaxone Market Analysis, by Distribution Channel
8. Global Ceftriaxone Market Analysis, by Region
8.1. Global Ceftriaxone Market Analysis, by Region
8.2. Global Ceftriaxone Market Value Share and Attractiveness Analysis, by Region
8.3. Global Ceftriaxone Market Forecast, by Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
9. North America Ceftriaxone Market Analysis
9.1. North America Ceftriaxone Market Overview
9.2. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Country
9.3. North America Ceftriaxone Market Forecast, by Country
9.3.1. U.S.
9.3.2. Canada
9.4. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
9.5. North America Ceftriaxone Market Forecast, by Indication
9.5.1. Urinary Tract Infections
9.5.2. Intra-abdominal Infections
9.5.3. Endocarditis
9.5.4. Acute Bacterial Otitis Media
9.5.5. Meningitis
9.5.6. Pneumonia
9.5.7. Others
9.6. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
9.7. North America Ceftriaxone Market Forecast, by Distribution Channel
9.7.1. Hospital Pharmacies
9.7.2. Retail Pharmacies
9.7.3. Online Pharmacies
10. Europe Ceftriaxone Market Analysis
10.1. Europe Ceftriaxone Market Overview
10.2. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
10.3. Europe Ceftriaxone Market Forecast, by Country/Sub-region
10.3.1. Germany
10.3.2. U.K.
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
10.5. Europe Ceftriaxone Market Forecast, by Indication
10.5.1. Urinary Tract Infections
10.5.2. Intra-abdominal Infections
10.5.3. Endocarditis
10.5.4. Acute Bacterial Otitis Media
10.5.5. Meningitis
10.5.6. Pneumonia
10.5.7. Others
10.6. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
10.7. Europe Ceftriaxone Market Forecast, by Distribution Channel
10.7.1. Hospital Pharmacies
10.7.2. Retail Pharmacies
10.7.3. Online Pharmacies
11. Asia Pacific Ceftriaxone Market Analysis
11.1. Asia Pacific Ceftriaxone Market Overview
11.2. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.3. Asia Pacific Ceftriaxone Market Forecast, by Country/Sub-region
11.3.1. China
11.3.2. India
11.3.3. Japan
11.3.4. Australia & New Zealand
11.3.5. Rest of Asia Pacific
11.4. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
11.5. Asia Pacific Ceftriaxone Market Forecast, by Indication
11.5.1. Urinary Tract Infections
11.5.2. Intra-abdominal Infections
11.5.3. Endocarditis
11.5.4. Acute Bacterial Otitis Media
11.5.5. Meningitis
11.5.6. Pneumonia
11.5.7. Others
11.6. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
11.7. Asia Pacific Ceftriaxone Market Forecast, by Distribution Channel
11.7.1. Hospital Pharmacies
11.7.2. Retail Pharmacies
11.7.3. Online Pharmacies
12. Latin America Ceftriaxone Market Analysis
12.1. Latin America Ceftriaxone Market Overview
12.2. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.3. Latin America Ceftriaxone Market Forecast, by Country/Sub-region
12.3.1. Brazil
12.3.2. Mexico
12.3.3. Rest of Latin America
12.4. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
12.5. Latin America Ceftriaxone Market Forecast, by Indication
12.5.1. Urinary Tract Infections
12.5.2. Intra-abdominal Infections
12.5.3. Endocarditis
12.5.4. Acute Bacterial Otitis Media
12.5.5. Meningitis
12.5.6. Pneumonia
12.5.7. Others
12.6. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
12.7. Latin America Ceftriaxone Market Forecast, by Distribution Channel
12.7.1. Hospital Pharmacies
12.7.2. Retail Pharmacies
12.7.3. Online Pharmacies
13. Middle East & Africa Ceftriaxone Market Analysis
13.1. Middle East & Africa Ceftriaxone Market Overview
13.2. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.3. Middle East & Africa Ceftriaxone Market Forecast, by Country/Sub-region
13.3.1. GCC Countries
13.3.2. South Africa
13.3.3. Rest of Middle East & Africa
13.4. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
13.5. Middle East & Africa Ceftriaxone Market Forecast, by Indication
13.5.1. Urinary Tract Infections
13.5.2. Intra-abdominal Infections
13.5.3. Endocarditis
13.5.4. Acute Bacterial Otitis Media
13.5.5. Meningitis
13.5.6. Pneumonia
13.5.7. Others
13.6. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
13.7. Middle East & Africa Ceftriaxone Market Forecast, by Distribution Channel
13.7.1. Hospital Pharmacies
13.7.2. Retail Pharmacies
13.7.3. Online Pharmacies
14. Competitive Analysis
14.1. Competition Matrix
14.2. Market Share Analysis, by Company, 2021
14.3. Company Profile
14.3.1. Hikma Pharmaceuticals plc
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. Strategic Overview
14.3.1.5. SWOT Analysis
14.3.2. Qilu Pharmaceutical Co. Ltd.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. Strategic Overview
14.3.2.5. SWOT Analysis
14.3.3. Novartis AG
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. Strategic Overview
14.3.3.5. SWOT Analysis
14.3.4. Baxter International, Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. Strategic Overview
14.3.4.5. SWOT Analysis
14.3.5. Aurobindo Pharma
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Strategic Overview
14.3.5.4. SWOT Analysis
14.3.6. ACS DOBFAR S.P.A.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Strategic Overview
14.3.6.4. SWOT Analysis
14.3.7. Orchid Pharma
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Strategic Overview
14.3.7.4. SWOT Analysis
14.3.8. Nectar Lifesciences Ltd.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. Strategic Overview
14.3.8.5. SWOT Analysis
14.3.9. Lupin Pharmaceuticals, Inc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. Strategic Overview
14.3.9.5. SWOT Analysis

ページTOPに戻る



図表リスト

List of Tables

Table 01: Global Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 02: Global Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 03: Global Ceftriaxone Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 04: North America Ceftriaxone Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 05: North America Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 06: North America Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 07: Europe Ceftriaxone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 08: Europe Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 09: Europe Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 10: Asia Pacific Ceftriaxone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 11: Asia Pacific Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 12: Asia Pacific Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Latin America Ceftriaxone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Latin America Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 15: Latin America Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 16: Middle East & Africa Ceftriaxone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Middle East & Africa Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 18: Middle East & Africa Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

 

ページTOPに戻る


 

Summary

Ceftriaxone Market – Scope of Report
TMR’s report on the global ceftriaxone market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global ceftriaxone market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global ceftriaxone market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the ceftriaxone market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global ceftriaxone market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global ceftriaxone market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global ceftriaxone market.

The report delves into the competitive landscape of the global ceftriaxone market. Key players operating in the global ceftriaxone market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global ceftriaxone market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market ceftriaxone.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.



ページTOPに戻る


Table of Contents

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
2. Assumptions and Research Methodology
2.1. Assumptions and Acronyms Used
2.2. Research Methodology
3. Executive Summary
3.1. Market Overview
3.2. Introduction
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunity
4.4. Global Ceftriaxone Market Forecast
4.5. Global Ceftriaxone Market Outlook
5. Market Outlook
5.1. Key Market Trends
5.2. Regulatory Scenario, by Region
5.3. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
6. Global Ceftriaxone Market Analysis and Forecast, by Indication
6.1. Introduction
6.2. Global Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
6.3. Global Ceftriaxone Market Forecast, by Indication
6.3.1. Urinary Tract Infections
6.3.2. Intra-abdominal Infections
6.3.3. Endocarditis
6.3.4. Acute Bacterial Otitis Media
6.3.5. Meningitis
6.3.6. Pneumonia
6.3.7. Others
7. Global Ceftriaxone Market Analysis and Forecast, by Distribution Channel
7.1. Introduction
7.2. Global Ceftriaxone Market Value Share Analysis, by Distribution Channel
7.3. Global Ceftriaxone Market Forecast, by Distribution Channel
7.3.1. Hospital Pharmacies
7.3.2. Retail Pharmacies
7.3.3. Online Pharmacies
7.4. Global Ceftriaxone Market Analysis, by Distribution Channel
8. Global Ceftriaxone Market Analysis, by Region
8.1. Global Ceftriaxone Market Analysis, by Region
8.2. Global Ceftriaxone Market Value Share and Attractiveness Analysis, by Region
8.3. Global Ceftriaxone Market Forecast, by Region
8.3.1. North America
8.3.2. Europe
8.3.3. Asia Pacific
8.3.4. Latin America
8.3.5. Middle East & Africa
9. North America Ceftriaxone Market Analysis
9.1. North America Ceftriaxone Market Overview
9.2. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Country
9.3. North America Ceftriaxone Market Forecast, by Country
9.3.1. U.S.
9.3.2. Canada
9.4. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
9.5. North America Ceftriaxone Market Forecast, by Indication
9.5.1. Urinary Tract Infections
9.5.2. Intra-abdominal Infections
9.5.3. Endocarditis
9.5.4. Acute Bacterial Otitis Media
9.5.5. Meningitis
9.5.6. Pneumonia
9.5.7. Others
9.6. North America Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
9.7. North America Ceftriaxone Market Forecast, by Distribution Channel
9.7.1. Hospital Pharmacies
9.7.2. Retail Pharmacies
9.7.3. Online Pharmacies
10. Europe Ceftriaxone Market Analysis
10.1. Europe Ceftriaxone Market Overview
10.2. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
10.3. Europe Ceftriaxone Market Forecast, by Country/Sub-region
10.3.1. Germany
10.3.2. U.K.
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Rest of Europe
10.4. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
10.5. Europe Ceftriaxone Market Forecast, by Indication
10.5.1. Urinary Tract Infections
10.5.2. Intra-abdominal Infections
10.5.3. Endocarditis
10.5.4. Acute Bacterial Otitis Media
10.5.5. Meningitis
10.5.6. Pneumonia
10.5.7. Others
10.6. Europe Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
10.7. Europe Ceftriaxone Market Forecast, by Distribution Channel
10.7.1. Hospital Pharmacies
10.7.2. Retail Pharmacies
10.7.3. Online Pharmacies
11. Asia Pacific Ceftriaxone Market Analysis
11.1. Asia Pacific Ceftriaxone Market Overview
11.2. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
11.3. Asia Pacific Ceftriaxone Market Forecast, by Country/Sub-region
11.3.1. China
11.3.2. India
11.3.3. Japan
11.3.4. Australia & New Zealand
11.3.5. Rest of Asia Pacific
11.4. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
11.5. Asia Pacific Ceftriaxone Market Forecast, by Indication
11.5.1. Urinary Tract Infections
11.5.2. Intra-abdominal Infections
11.5.3. Endocarditis
11.5.4. Acute Bacterial Otitis Media
11.5.5. Meningitis
11.5.6. Pneumonia
11.5.7. Others
11.6. Asia Pacific Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
11.7. Asia Pacific Ceftriaxone Market Forecast, by Distribution Channel
11.7.1. Hospital Pharmacies
11.7.2. Retail Pharmacies
11.7.3. Online Pharmacies
12. Latin America Ceftriaxone Market Analysis
12.1. Latin America Ceftriaxone Market Overview
12.2. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
12.3. Latin America Ceftriaxone Market Forecast, by Country/Sub-region
12.3.1. Brazil
12.3.2. Mexico
12.3.3. Rest of Latin America
12.4. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
12.5. Latin America Ceftriaxone Market Forecast, by Indication
12.5.1. Urinary Tract Infections
12.5.2. Intra-abdominal Infections
12.5.3. Endocarditis
12.5.4. Acute Bacterial Otitis Media
12.5.5. Meningitis
12.5.6. Pneumonia
12.5.7. Others
12.6. Latin America Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
12.7. Latin America Ceftriaxone Market Forecast, by Distribution Channel
12.7.1. Hospital Pharmacies
12.7.2. Retail Pharmacies
12.7.3. Online Pharmacies
13. Middle East & Africa Ceftriaxone Market Analysis
13.1. Middle East & Africa Ceftriaxone Market Overview
13.2. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Country/Sub-region
13.3. Middle East & Africa Ceftriaxone Market Forecast, by Country/Sub-region
13.3.1. GCC Countries
13.3.2. South Africa
13.3.3. Rest of Middle East & Africa
13.4. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Indication
13.5. Middle East & Africa Ceftriaxone Market Forecast, by Indication
13.5.1. Urinary Tract Infections
13.5.2. Intra-abdominal Infections
13.5.3. Endocarditis
13.5.4. Acute Bacterial Otitis Media
13.5.5. Meningitis
13.5.6. Pneumonia
13.5.7. Others
13.6. Middle East & Africa Ceftriaxone Market Value Share and Attractiveness Analysis, by Distribution Channel
13.7. Middle East & Africa Ceftriaxone Market Forecast, by Distribution Channel
13.7.1. Hospital Pharmacies
13.7.2. Retail Pharmacies
13.7.3. Online Pharmacies
14. Competitive Analysis
14.1. Competition Matrix
14.2. Market Share Analysis, by Company, 2021
14.3. Company Profile
14.3.1. Hikma Pharmaceuticals plc
14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.1.2. Product Portfolio
14.3.1.3. Financial Overview
14.3.1.4. Strategic Overview
14.3.1.5. SWOT Analysis
14.3.2. Qilu Pharmaceutical Co. Ltd.
14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.2.2. Product Portfolio
14.3.2.3. Financial Overview
14.3.2.4. Strategic Overview
14.3.2.5. SWOT Analysis
14.3.3. Novartis AG
14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.3.2. Product Portfolio
14.3.3.3. Financial Overview
14.3.3.4. Strategic Overview
14.3.3.5. SWOT Analysis
14.3.4. Baxter International, Inc.
14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.4.2. Product Portfolio
14.3.4.3. Financial Overview
14.3.4.4. Strategic Overview
14.3.4.5. SWOT Analysis
14.3.5. Aurobindo Pharma
14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.5.2. Product Portfolio
14.3.5.3. Strategic Overview
14.3.5.4. SWOT Analysis
14.3.6. ACS DOBFAR S.P.A.
14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.6.2. Product Portfolio
14.3.6.3. Strategic Overview
14.3.6.4. SWOT Analysis
14.3.7. Orchid Pharma
14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.7.2. Product Portfolio
14.3.7.3. Strategic Overview
14.3.7.4. SWOT Analysis
14.3.8. Nectar Lifesciences Ltd.
14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.8.2. Product Portfolio
14.3.8.3. Financial Overview
14.3.8.4. Strategic Overview
14.3.8.5. SWOT Analysis
14.3.9. Lupin Pharmaceuticals, Inc.
14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
14.3.9.2. Product Portfolio
14.3.9.3. Financial Overview
14.3.9.4. Strategic Overview
14.3.9.5. SWOT Analysis

ページTOPに戻る



List of Tables/Graphs

List of Tables

Table 01: Global Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 02: Global Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 03: Global Ceftriaxone Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 04: North America Ceftriaxone Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 05: North America Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 06: North America Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 07: Europe Ceftriaxone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 08: Europe Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 09: Europe Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 10: Asia Pacific Ceftriaxone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 11: Asia Pacific Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 12: Asia Pacific Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 13: Latin America Ceftriaxone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Latin America Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 15: Latin America Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 16: Middle East & Africa Ceftriaxone Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Middle East & Africa Ceftriaxone Market Value (US$ Mn) Forecast, by Indication, 2017–2031

Table 18: Middle East & Africa Ceftriaxone Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(中枢神経系作用薬)の最新刊レポート

Transparency Market Research 社の最新刊レポート


よくあるご質問


Transparency Market Research社はどのような調査会社ですか?


トレンスペアレンシーマーケットリサーチ(Transparency Market Research /TMR)は市場参入やホワイトスペースの特定、新商品や新サービスの立ち上げ、戦略的M&Aなどの実現のた... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/10/01 10:26

145.10 円

161.88 円

196.72 円

ページTOPに戻る